Departament of Radiation Oncology, Hospital del Mar, Parc de Salut MAR, Passeig Marítim, 25-29, 08003, Barcelona, Spain.
Hospital del Mar Medical Research Institute (IMIM), Doctor Aiguader 88, 08003, Barcelona, Spain.
Clin Transl Oncol. 2017 Oct;19(10):1183-1192. doi: 10.1007/s12094-017-1667-5. Epub 2017 Apr 26.
Small-cell lung cancer (SCLC) accounts for 13% of all lung tumours. The standard treatment in patients with limited-stage disease is radiotherapy combined with chemotherapy. In extensive SCLC, the importance of consolidation thoracic radiotherapy in patients with a good treatment response has become increasingly recognized. In both limited and extensive disease, prophylactic cranial irradiation is recommended in patients who respond to treatment. New therapeutic approaches such as immunotherapy are being increasingly incorporated into the treatment of SCLC, although more slowly than in non-small cell lung cancer (NSCLC). Diverse radiation dose and fractionation schemes, administered in varying combinations with these new drugs, are being investigated. In the present study we review and update the role of radiotherapy in the treatment of SCLC. We also discuss the main clinical trials currently underway in order to identify future trends.
小细胞肺癌(SCLC)约占所有肺癌的 13%。局限期疾病患者的标准治疗是放疗联合化疗。在广泛期 SCLC 中,治疗反应良好的患者接受巩固性胸部放疗的重要性日益得到认可。在局限期和广泛期疾病中,对治疗有反应的患者推荐预防性颅脑照射。免疫疗法等新的治疗方法越来越多地被纳入 SCLC 的治疗中,尽管速度比非小细胞肺癌(NSCLC)慢。不同的放疗剂量和分割方案,与这些新药联合应用,正在被研究中。在本研究中,我们回顾和更新了放疗在 SCLC 治疗中的作用。我们还讨论了目前正在进行的主要临床试验,以确定未来的趋势。